Peanut Allergy

CTAF

ICER will assess the comparative clinical effectiveness and value of treatments for peanut allergy. The report is expected to focus on two therapies: Viaskin® Peanut (DBV Technologies), which is currently undergoing FDA review with an approval decision expected in mid-2019, and AR101 (Aimmune Therapeutics). Aimmune has announced its intention to submit a biologics license application with the FDA by the end of 2018 for AR101. This list is tentative and subject to change.

Associated Meetings

June 11, 2019 10AM-4PM

Oakland, CA

CTAF will convene to review ICER's assessment of treatments for peanut allergy.


Key Dates

Associated Materials

11/20/2018
Draft Scoping Document

12/20/2018
Revised Scoping Document

04/11/2019
Draft Evidence Report

05/30/2019
Evidence Report

06/11/2019
Evidence Presentation